News & Insights
August 6, 2025 K&S obtains a favorable ruling on behalf of Motive Technologies before a California federal court, which ruled there is no basis for a new trial
July 31, 2025 K&S secures a complete defense verdict on behalf of CG Oncology in a dispute with ANI Pharmaceuticals over future royalties on net sales of cretostimogene or, in the alternative, $2.3B in unjust enrichment damages
July 29, 2025 King & Spalding Secures Complete Defense Verdict for CG Oncology in Defense of Future Royalties and $2.3 Billion Unjust Enrichment Claim
May 9, 2025 K&S advises Motive Technologies following a win in a patent infringement suit in a bid for post-trial judgment by Omnitracs, XRS Corporation and SmartDrive before a California federal court